ResMed Inc. filed its annual report on Form 10-K with the U.S. Securities and Exchange Commission on August 13, 2026, covering the fiscal year ended June 30, 2026, and disclosing key financial and operational information for the Delaware-incorporated medical device company.
Key Highlights
- Fiscal year covered: The report covers the twelve-month period ended June 30, 2026.
- Shares outstanding: As of August 10, 2026, ResMed had 144,252,306 shares of Common Stock, $0.004 par value, issued and outstanding, excluding 46,798,043 treasury shares.
- Market capitalization of non-affiliate equity: The aggregate market value of voting and non-voting common equity held by non-affiliates was $34,917,180,979 as of December 31, 2025.
- Large accelerated filer: ResMed is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act, according to the filing.
- Exchange listing: ResMed's common stock trades on the New York Stock Exchange under the symbol NYSE:RMD.
- Internal controls attestation: The company disclosed that its registered public accounting firm filed a report and attestation on management's assessment of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
ResMed's Fiscal 2026 Annual Report: Key Corporate and Financial Disclosures
ResMed Inc., a Delaware corporation headquartered at 9001 Spectrum Center Blvd., San Diego, CA 92123, filed its Form 10-K for the fiscal year ended June 30, 2026. The company, which operates in the medical device and software sectors with products and services focused on sleep and respiratory health, confirmed that it had filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months, according to the filing. ResMed is identified in the filing as a well-known seasoned issuer as defined in Rule 405 of the Securities Act.
The filing reports that as of August 10, 2026, ResMed had 144,252,306 shares of Common Stock outstanding, with 46,798,043 additional shares held as treasury shares and therefore excluded from that count. The aggregate market value of common equity held by non-affiliates - computed using the closing sale price on the New York Stock Exchange as of December 31, 2025, the last business day of the registrant's most recently completed second fiscal quarter - was reported as $34,917,180,979. The filing notes that all directors, executive officers, and 10% stockholders are considered affiliates for purposes of this calculation.
ResMed's annual report encompasses a broad range of disclosures across its four Parts, including business description, risk factors, cybersecurity, management's discussion and analysis, and consolidated financial statements. The filing also notes that portions of the company's definitive Proxy Statement, to be filed within 120 days after the close of the fiscal year, will be incorporated by reference into Part III of the report. The forward-looking statements included in the filing are attributed to management's beliefs and estimates and are described by the company as subject to a number of risks, uncertainties, and assumptions, including changes in healthcare reform, macroeconomic conditions, geopolitical factors, and tariff impacts.
What Was Disclosed
ResMed Inc. submitted its fiscal year 2026 annual report disclosing share count, non-affiliate market capitalization, filer classification, internal control attestation status, and the broad scope of its business and risk disclosures for the period ended June 30, 2026.




Please wait processing your request...